Lantern Pharma is trading 7.4% lower at $0.84, with no company-specific news explaining the decline. - Lantern Pharma announced a ThinkEquity Conference presentation for October 15; Taiwan approval to advance its HARMONIC trial was reported October 7. Neither directly accounts for the drop. - Broader risk-off conditions may be adding pressure as oil surged above $105 a barrel and Treasury yields remained near multi-year highs. Reuters reported inflation concerns pressuring stocks, while major indexes fell less than 0.5%.